Explanation: The Serum Institute of India, founded in 1966, is a leading vaccine manufacturer based in Pune, India. It is renowned for its large-scale production of vaccines at affordable prices, making it the world's largest vaccine manufacturer by the number of doses produced annually. The company produces a wide range of vaccines, including those for diseases such as diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib).
The Serum Institute collaborates with various global health organizations, including the World Health Organization (WHO) and Gavi, the Vaccine Alliance, to ensure that vaccines are accessible to people in low-income countries. This collaboration has been crucial in addressing global health challenges and ensuring that vaccines are available to those who need them most.
Biocon, while a significant player in the Indian pharmaceutical industry, focuses more on biotechnology and biotherapeutics rather than vaccine production on the scale of the Serum Institute. Indian Immunologicals also produces vaccines and biological products, but its production scale is not as extensive as that of the Serum Institute. Bharat Biotech, known for developing the Covaxin COVID-19 vaccine, is a notable player in the vaccine market but does not match the Serum Institute's production scale.
Understanding the role of the Serum Institute in global health is essential for comprehending the dynamics of vaccine production and distribution. The company's ability to produce vaccines at a large scale and affordable prices has made a significant impact on global health initiatives, particularly in addressing vaccine shortages in low-income countries. This underscores the importance of the Serum Institute in the context of global health and vaccine accessibility.